Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Fiche publication
Date publication
août 2023
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESMOULINS Isabelle, Dr JOUANNAUD Christelle
Tous les auteurs :
Le Du F, Carton M, Bachelot T, Saghatchian M, Pistilli B, Brain E, Loirat D, Vanlemmens L, Vermeulin T, Emile G, Gonçalves A, Ung M, Robert M, Jaffre A, Desmoulins I, Jouannaud C, Uwer L, Marc Ferrero J, Mouret-Reynier MA, Jacot W, Chevrot M, Delaloge S, Diéras V
Lien Pubmed
Résumé
Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as whether (neo)adjuvant anti-HER2 treatments impact the patterns of recurrence and outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC). We aimed to assess this in the large multicenter ESME real-world database.
Mots clés
HER2 positive, anti-HER2-targeted agents, breast cancer, de novo metastatic, pertuzumab, trastuzumab
Référence
Oncologist. 2023 08 17;: